+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references 29

          • Record: found
          • Abstract: found
          • Article: found

          ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

           M. Pavel (corresponding) ,  D. O''Toole,  F. Costa (2016)
            • Record: found
            • Abstract: found
            • Article: found

            ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

             M. Falconi (corresponding) ,  B Eriksson,  G. Kaltsas (2016)
              • Record: found
              • Abstract: found
              • Article: not found

              Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

              Atrophic gastritis, intestinal metaplasia, and epithelial dysplasia of the stomach are common and are associated with an increased risk for gastric cancer. In the absence of guidelines, there is wide disparity in the management of patients with these premalignant conditions. The European Society of Gastrointestinal Endoscopy (ESGE), the European Helicobacter Study Group (EHSG), the European Society of Pathology (ESP) and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) have therefore combined efforts to develop evidence-based guidelines on the management of patients with precancerous conditions and lesions of the stomach (termed MAPS). A multidisciplinary group of 63 experts from 24 countries developed these recommendations by means of repeat online voting and a meeting in June 2011 in Porto, Portugal. The recommendations emphasize the increased cancer risk in patients with gastric atrophy and metaplasia, and the need for adequate staging in the case of high grade dysplasia, and they focus on treatment and surveillance indications and methods. © Georg Thieme Verlag KG Stuttgart · New York.

                Author and article information

                S. Karger AG
                April 2016
                19 January 2016
                : 103
                : 2
                : 119-124
                aDepartment of Digestive and Liver Disease, Ospedale Sant'Andrea, Rome, Italy; bNET Centre, St. Vincent's University and Department of Clinical Medicine, St. James Hospital and Trinity College, Dublin, Ireland; cDepartment of Radiology, Section for Molecular Imaging, University Hospital, Uppsala, Sweden; dNetherlands Cancer Centre, Lijnden, The Netherlands; eNET Centre, Umbria Regional Cancer Network, Università degli Studi di Perugia, Perugia, Italy; fGastroenterology Department, Hampshire Hospitals NHS Trust, Hampshire, UK; gDepartment of Endocrine and Metabolic Sciences, University of Genoa, Genoa, Italy; hPancreatic Diseases Branch, Kyushu University Hospital, Fukuoka, Japan; iDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, N.Y., USA; jDepartment of Endocrinology, Peking Union Medical College Hospital, Beijing, China; kDepartment of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands; lDepartment of Visceral and Transplant Surgery, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany; mDepartment of Gastroenterology, Beaujon Hospital, Clichy, France
                Author notes
                *Gianfranco Delle Fave, MD, PhD, Department of Digestive and Liver Disease, Sapienza University of Rome, Via di Grottarossa 1035, IT-00189 Rome (Italy), E-Mail gianfranco.dellefave@uniroma1.it
                443168 Neuroendocrinology 2016;103:119-124
                © 2016 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Figures: 2, Tables: 1, References: 36, Pages: 6
                ENETS Consensus Guidelines


                Comment on this article